Filing summary
Issuer discrepancy: The filing identifies the company as AcelRx Pharmaceuticals, Inc., not Talphera, Inc. Confirm that this is the intended filing before relying on the information below.
Business context and reporting period
This is AcelRx’s unaudited Form 10-Q for the quarter and six months ended June 30, 2013. AcelRx was a development-stage specialty pharmaceutical company developing treatments for acute and breakthrough pain. It had no product sales; reported revenue was research-grant revenue. Its lead candidate, Zalviso (ARX-01), was an investigational hospital pain-management system, and ARX-04 was an earlier-stage acute-pain candidate.
Financial performance and liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Research-grant revenue | 2013: $0.407 million; 2012: $0.224 million | 2013: $1.347 million; 2012: $0.553 million |
| Research and development expense | 2013: $6.108 million; 2012: $5.394 million | 2013: $15.426 million; 2012: $10.165 million |
| General and administrative expense | 2013: $2.070 million; 2012: $1.776 million | 2013: $4.261 million; 2012: $3.880 million |
| Net loss | 2013: $17.447 million; 2012: $7.194 million | 2013: $30.209 million; 2012: $14.259 million |
| Basic and diluted loss per share | 2013: $0.47; 2012: $0.35 | 2013: $0.81; 2012: $0.71 |
| Cash used in operating activities | Six-month 2013: $19.096 million; six-month 2012: $12.100 million |
At June 30, 2013, cash, cash equivalents and investments totaled $36.844 million, down from $59.763 million at December 31, 2012. Current assets were $35.226 million and current liabilities $12.121 million; reported working capital was $23.1 million. Total liabilities were $34.756 million. Hercules debt was approximately $12.4 million, bearing 8.5% interest and scheduled to mature December 1, 2014; the debt is secured by substantially all assets other than intellectual property. No operating margin is meaningfully indicated given the absence of product sales and the company’s development-stage losses.
Material changes and unusual items
- Six-month operating expenses increased to $19.687 million from $14.045 million. R&D growth reflected higher Zalviso Phase 3 and ARX-04 Phase 2 development spending, as well as personnel costs.
- Net loss increased substantially, principally because of a $10.4 million six-month increase in the estimated fair value of PIPE warrant liabilities, recorded as other expense. The warrant liability rose to $17.850 million from $7.418 million at year-end. This remeasurement was noncash; the filing says the increase was primarily driven by the higher share price.
- Six-month operating cash use rose to $19.096 million. Financing cash flow was negative $3.587 million, primarily reflecting Hercules loan repayments.
- On July 23, 2013, after quarter-end, AcelRx raised approximately $47.9 million net in an underwritten offering of 4.37 million shares at $11.65 per share. Management said existing resources, including these proceeds, were expected to fund current operations through at least 2014.
Outlook, commentary and risks
- Management anticipated submitting a Zalviso New Drug Application to the FDA in the third quarter of 2013. All three Phase 3 trials had met their primary endpoints, according to the filing; approval, timing and commercial success were not assured.
- Management expected second-half 2013 R&D expense to be lower than first-half quarterly levels as clinical development spending declined, partly offset by NDA preparation. Full-year 2013 operating expenses were expected to be modestly higher than in 2012; G&A was expected to increase with commercial preparation and infrastructure build-out.
- The $5.6 million USAMRMC grant for ARX-04 had been extended through January 31, 2014. The company expected to earn the remaining approximately $0.8 million by then; further ARX-04 development depended on additional resources. Development of ARX-02 and ARX-03 also depended on partnership resources.
- Key risks include FDA review of a drug-device combination, possible further study requirements or labeling restrictions, opioid-related safety and REMS requirements, manufacturing scale-up and single-source supply exposure, DEA-controlled sufentanil quotas, competition and hospital adoption, and the need for additional capital after the forecast funding period.
- The filing reported no material pending litigation, no off-balance-sheet arrangements, and effective disclosure controls at the reasonable-assurance level.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for AcelRx Pharmaceuticals, Inc., not Talphera, Inc.
- Check subsequent filings for whether and when the Zalviso NDA was submitted, accepted for review, and acted upon by the FDA, including any additional study or labeling requirements.
- Verify the July 2013 offering’s final net proceeds, share dilution and updated cash runway against later reported results and cash burn.
- Review the assumptions and accounting impact of the $17.850 million warrant liability, including its potential volatility and eventual settlement terms.
- Track Hercules debt repayments and maturity, plus Patheon manufacturing readiness, supply continuity and any facility or validation spending.
- Assess whether grant funding or partnerships support continued ARX-04, ARX-02 and ARX-03 development, and whether commercialization plans require further financing.